Prevention of opportunistic infections in the era of improved antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue SUPPL. 1, 1997, Pages

  Chaisson, Richard E ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral; HIV; Opportunistic infections; Prophylaxis; USPHS IDSA guidelines

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RETROVIRUS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS; INCIDENCE; PATIENT COMPLIANCE; RISK FACTORS; SURVIVORS;

HUMAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030732704     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199701001-00003     Document Type: Article

References (41)

1. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
2. + T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. Arch Intern Med 1995;155:1537-42.
3. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
4. Kaplan JE, Masur H, Holmes KK, et al., and the USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. Clin Infect Dis 1995;21(suppl 1):S1-11.
5. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV-infection. Ann Intern Med 1996;124:654-63.
6. Ho DD, Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-1.
7. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
8. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-805.
9. Chaisson RE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in HIV disease [Abstract]. Proc Fourth Conf Retroviruses Opportunistic Infections, 1997.
10. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
11. Kaplan JE, Hu DJ, Holmes KK, Jaffe HW, Masur H, De Cock KM. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996;55:1-11.
12. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intent Med 1994; 120:932-44.
13. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, and the Zidovudine Epidemiology Study Group. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992;146:285-9.
14. Chaisson RE. Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Clin Infect Dis 1996;22(suppl 1):S61-9.
15. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
16. Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A, and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
17. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
18. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-7.
19. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1643-8.
20. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-9.
21. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995;9:1337-42.
22. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
23. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Reducing the impact of opportunistic infections in patients with HIV infection. New guidelines. JAMA 1995;274:347-8.
24. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173: 219-25.
25. Bishai WR, Graham NM, Harrington S, et al. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996;334:1573-6.
26. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21 (suppl 1):S32-43.
27. Kadree MA. High prevalence of trimethoprim-sulfamethoxazole (TMP-SMX) resistant Streptococcus pneumoniae in HIV-infected patients on TMP-SMX for pneumocystis prophylaxis: therapeutic implications [Abstract]. Proc Eleventh Int Conf AIDS, 1996;B182.
28. Rodriguez-Barradas MC, Tharapel RA, Groover JE, et al. Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J Infect Dis 1997;175:590-7.
29. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996;101:34-40.
30. Kaplan JE, Masur H, Holmes KK, et al., and the USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995;21(suppl 1):S12-31.
31. Barditch-Crovo P, Chaisson RE. Adverse reactions to therapy for HIV infection. Emerg Med Clin North Am 1995;13:133-46.
32. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
33. Eldred LJ, Wu A, Chaisson RE, Moore RD. Medication adherence to long-term therapy in HIV disease [Abstract]. Proc Eleventh Int Conf AIDS, 1996;B1165.
34. Moore RD, Chaisson RE. Costs to medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: 223-31.
35. Aseltyne WJ, Cloutier M, Smith MD. HIV disease and managed care: an overview. J Acquir Immune Defic Syndr 1995;8(suppl 1):S11-22.
36. Moore RD, Chaisson RE. Cost-effectiveness of prophylaxis for Mycobacterium avium complex disease. Am J Med (in press).
37. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991;266: 820-4.
38. Moore RD, Chaisson RE. Cost-effectiveness of prophylaxis for cytomegalovirus disease in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retroviral 1997 (in press).
39. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
40. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997; 46(No. RR-12):1-46.
41. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.